Where the Money Goes

 

 

For some childhood cancers, treatment plans have not changed for decades. For some children, there will be no cure. We have a plan to change this—and the plan is the Crazy 8 Initiative.

The Commitment

Since our founding, Alex’s Lemonade Stand Foundation (ALSF) has promoted collaboration and working together to find cures.

In the spirit of growing scientific collaboration, ALSF has launched the Crazy 8 Initiative to detail roadmaps toward cures for specific, hard-to-treat childhood cancers. In addition to its current grant opportunities, the Crazy 8 Initiative creates a new funding pillar for ALSF, allowing the Foundation to tackle explicit challenges in pediatric cancer research that require substantial support for collaborative teams. ALSF has committed $25 million to support the Crazy 8 Initiative. In 2022, that commitment was raised to $26 million.

The Crazy 8 Initiative will fund research into innovative and rigorous approaches that directly address the most intractable issues in pediatric cancer research today. Project teams of cross-disciplinary scientists work collaboratively, accelerating the pace of new cure discovery, and each grant will provide funding for large-scale collaborative projects in the $1-5 million range.

We will create a future free of childhood cancer.

Support the Crazy 8 Initiative

The Crazy 8 Initiative Meeting

The Crazy 8 Initiative kicked off in the fall of 2018 with a meeting that brought together more than 90 top scientists from around the world to contribute their expertise in eight key areas of need:

  1. Embryonal brain cancers
  2. High-grade gliomas
  3. Fusion-positive sarcomas
  4. Fusion-negative sarcomas
  5. Leukemias
  6. Neuroblastoma
  7. Big data
  8. Catalyzing clinical trials

The meeting was chaired by Nada Jabado, MD/PhD of McGill University and John Maris, MD of Children’s Hospital of Philadelphia. The group aimed to undertake the big question: How can we tackle major obstacles impeding progress towards cures for childhood cancer through multidisciplinary collaborative research? 

To jump start the research ideas that came out of the Crazy 8 Initiative Meeting, ALSF supported 11 pilot projects in 2019, with at least one project for each Crazy 8 area of need. Learn more about the exciting Crazy 8 pilot projects here.

The 2020 Crazy 8 Initiative Award Selection Process

The outcomes of the Crazy 8 Initiative Meeting included a list of addressable problems and proposed pathways forward to overcome these obstacles to make cures a reality. Four cross-cutting research themes were identified:

  1. Developmental Origins of Pediatric Cancers
  2. Drugging Currently Undruggable Pediatric Cancer Drivers
  3. Developing Novel Immunotherapies
  4. Discovery of Novel Pediatric Cancer Drug Targets

Coupling the eight key areas of need with the four research themes allowed ALSF to develop Crazy 8 application guidelines and request from the scientific community, grant applications responsive to the spirit of the Crazy 8 Initiative.

After submission of letters of intent, 100 applicants were asked to submit full applications in January 2020. A rigorous peer-review of the applications resulted in the selection of 10 finalists for the award. The finalists presented their proposed project to the Crazy 8 Scientific Review Board and ALSF Leadership in Fall 2020. Final grant selections were then made for four outstanding projects which can be viewed here.

Learn About The Crazy 8 Projects

The 2021 Crazy 8 Initiative Award Selection Process and Next Steps

ALSF has committed $25 million to support research through the Crazy 8 Initiative. Approximately $18.5 million was allocated in the first round of funding in 2020, and ALSF is pleased to announce $6.1 million has been awarded in 2022 to two new projects. This brings the total support for the Initiative to $26 million.

Priority was given to projects involving innovative studies of high-grade gliomas, non-medulloblastoma embryonal brain tumors, non-Ewing Sarcoma fusion-positive sarcomas, fusion-negative sarcomas, big data and/or catalyzing clinical trials. ALSF received over 50 letters of intent from investigators with proposals focusing on leukemias, neuroblastoma, sarcomas and medulloblastoma. Of those, fourteen submissions were invited to submit a full proposal.

After a rigorous scientific review process, four finalists presented their proposed projects to the Crazy 8 Scientific Review Board and ALSF Leadership. Two exceptional projects focusing on osteosarcoma were selected. They can be viewed here.

Sign up for email updates